Skip to main content

Advertisement

Table 2 Improvement in PAP in patients with sarcoidosis-associated pulmonary hypertension following bosentan treatment

From: Pulmonary hypertension associated with sarcoidosis

Patient Initial mean PAP (mmHg) Follow-up mean PAP (mmHg) Pulmonary hypertension therapy Other sarcoidosis medications
1 73 41 Epoprostenol Prednisone, methotrexate, azathioprine, infliximab
2a 63 45 Bosentan Prednisone
3a 61 ND Bosentan, epoprostenol Prednisone, azathioprine
4 53 23 Amlodipine Prednisone, methotrexate
5 50 ND Bosentan Prednisone, methotrexate
6 38 36 Bosentan Prednisone, methotrexate, azathioprine
7 36 24 Bosentan Prednisone, methotrexate, infliximab
  1. Shown are data demonstrating improvement in pulmonary artery pressure (PAP) following addition of bosentan to standard anti-inflammatory therapy in a small cohort of patients with sarcoidosis-associated pulmonary hypertension. aPatient died. ND, not determined.